SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-040136
Filing Date
2023-11-09
Accepted
2023-11-09 17:25:11
Documents
14
Period of Report
2023-11-07
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 59890
2 ex99-1.htm EX-99.1 28221
3 ex99-1_001.jpg GRAPHIC 14874
  Complete submission text file 0001493152-23-040136.txt   292145

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mtnb-20231107.xsd EX-101.SCH 3039
5 XBRL LABEL FILE mtnb-20231107_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE mtnb-20231107_pre.xml EX-101.PRE 22375
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3415
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

IRS No.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 231393888
SIC: 2834 Pharmaceutical Preparations